Government-Owned Inventions; Availability for Licensing, 41588-41589 [2016-15057]
Download as PDF
<![CDATA[
41588
Federal Register / Vol. 81, No. 123 / Monday, June 27, 2016 / Notices
Health, 6701 Rockledge Drive, Room 4196,
MSC 7812, Bethesda, MD 20892; 301–435–
2902; gubina@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Eye Institute; Notice of Closed
Meeting
National Eye Institute; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Eye Institute
Special Emphasis Panel; NEI Clinical
Cooperative Agreement and ClinicallyOriented Applications.
Date: July 28, 2016.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health, 5635
Fisher Lane, Rockville, MD 20814
(Telephone Conference Call).
Contact Person: Brian Hoshaw, Ph.D.,
Scientific Review Officer, National Eye
Institute, National Institutes of Health,
Division of Extramural Research, 5635
Fishers Lane, Suite 1300, Rockville, MD
20892, 301–451–2020, hoshawb@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.867, Vision Research,
National Institutes of Health, HHS)
Dated: June 21, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–15055 Filed 6–24–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
mstockstill on DSK3G9T082PROD with NOTICES
National Institutes of Health
Name of Committee: National Eye Institute
Special Emphasis Panel; NEI Data Analysis
and Epidemiology Grant Applications.
Date: July 18–19, 2016.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5635
Fishers Lane, Bethesda, MD 20892, (Virtual
Meeting).
Contact Person: Jeanette M. Hosseini,
Ph.D., Scientific Review Officer, 5635 Fishers
Lane, Suite 1300, Bethesda, MD 20892, 301–
451–2020, jeanetteh@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.867, Vision Research,
National Institutes of Health, HHS)
Dated: June 21, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–15061 Filed 6–24–16; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
18:52 Jun 24, 2016
Jkt 238001
Dated: June 21, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–15063 Filed 6–24–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
co-owned by an agency of the U.S.
Government and is available for
licensing and/or co-development in the
U.S. in accordance with 35 U.S.C. 209
SUMMARY:
PO 00000
Frm 00081
Fmt 4703
Sfmt 4703
and 37 CFR part 404 to achieve
expeditious commercialization of
results of federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing and/or co-development.
ADDRESSES: Invention Development and
Marketing Unit, Technology Transfer
Center, National Cancer Institute, 9609
Medical Center Drive, Mail Stop 9702,
Rockville, MD 20850–9702.
FOR FURTHER INFORMATION CONTACT:
Information on licensing and codevelopment research collaborations,
and copies of the U.S. patent
applications listed below may be
obtained by contacting: Attn. Invention
Development and Marketing Unit,
Technology Transfer Center, National
Cancer Institute, 9609 Medical Center
Drive, Mail Stop 9702, Rockville, MD
20850–9702, Tel. 240–276–5515 or
email ncitechtransfer@mail.nih.gov. A
signed Confidential Disclosure
Agreement may be required to receive
copies of the patent applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Title of invention: Anti- B-Cell
Maturation Antigen Antibodies for
Developing Cancer Therapeutics
Keywords: BCMA, Antibody,
Immunotoxin, Chimeric Antigen
Receptor (CAR), Antibody-drug
Conjugate (ADC), Bispecific Antibody,
Cancer, Myeloma,
Description of Technology: Multiple
Myeloma is a subtype of leukemia that
originates in bone marrow, where
normal plasma cells are produced.
Although FDA-approved antibody-based
therapy is available for other B-cell
malignancies, no effective antibodybased therapies are available for MM
due to the lack of specific target antigen
on MM cells. BCMA (B-Cell Maturation
Antigen), is a membrane antigen
selectively expressed on mature Blymphocytes and in all MM cells from
patients. Thus, BCMA shows promise as
a target for immune-based therapy.
This technology concerns the
generation of several monoclonal
antibodies against BCMA. These
antibodies can be utilized
therapeutically in several ways,
including as recombinant
immunotoxins, chimeric antigen
receptors (CARs), antibody-drug
conjugates (ADCs), bispecific
antibodies, and as unconjugated
antibodies. The antibodies can also be
use in diagnostic applications. It is
important to note that several
conjugated immunotoxins using the
antibodies of this invention have
E:\FR\FM\27JNN1.SGM
27JNN1
Federal Register / Vol. 81, No. 123 / Monday, June 27, 2016 / Notices
already exhibited high efficacy against
MM cells in recent in vitro studies.
Potential Commercial Applications:
• Therapeutic Uses
Æ Use as an unconjugated antibody
Æ Use as a targeting moiety for
immunoconjugates such as CARs,
ADCs, immunoconjugates,
bispecific antibodies, etc.
• Diagnostic agent for detecting and
monitoring BCMA-expressing
malignancies
Value Proposition:
• First to market potential—There are
no current targeted therapeutics for
BCMA
• High specificity and binding to BCMA
results in less non-specific cell
killing, therefore fewer potential
side-effects for the patient
• Chimeric Antigen Receptor-based
therapies have been successful
against B-cell lineage cancer; an
anti-BCMA CAR represents a highly
effective therapeutic candidate
Development Stage: In-vitro testing.
Inventor(s): Ira Pastan (NCI), Tapan
Bera (NCI), Satoshi Nagata (Sanford
Research Center), and Tomoko Ise
(Sanford Research Center).
Intellectual Property:
US Provisional Application 62/
255,255 (HHS Reference No. E–
010–2016/0–US–01) filed
November 13, 2015 entitled ‘‘AntiBCMA Polypeptides and
Conjugates’’;
US Provisional Application 62/
257,493 (HHS Reference No. E–
010–2016/1–US–01) filed
November 19, 2015 entitled ‘‘AntiBCMA Polypeptides and Proteins’’
Contact Information: Requests for
copies of the patent application or
inquiries about licensing, and codevelopment research collaborations
should be sent to John D. Hewes, Ph.D.
email: john.hewes@nih.gov or phone:
240–276–5515.
Dated: June 20, 2016.
John D. Hewes,
Technology Transfer Specialist, Technology
Transfer Center, National Cancer Institute.
[FR Doc. 2016–15057 Filed 6–24–16; 8:45 am]
BILLING CODE 4140–01–P
mstockstill on DSK3G9T082PROD with NOTICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Eye Institute; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
VerDate Sep<11>2014
18:52 Jun 24, 2016
Jkt 238001
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Eye Institute
Special Emphasis Panel; NEI Clinical
Cooperative Agreement Applications.
Date: July 25, 2016.
Time: 11:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health, 5635
Fishers Lane, Rockville, MD 20852
(Telephone Conference Call).
Contact Person: Brian Hoshaw, Ph.D.,
Scientific Review Officer, National Eye
Institute, National Institutes of Health,
Division of Extramural Research, 5635
Fishers Lane, Suite 1300, Rockville, MD
20892, 301–451–2020, hoshawb@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.867, Vision Research,
National Institutes of Health, HHS)
Dated: June 21, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–15062 Filed 6–24–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
41589
Date: July 7, 2016.
Time: 1:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Elizabeth Webber, Ph.D.,
Scientific Review Administrator, Scientific
Review Branch, NINDS/NIH/DHHS,
Neuroscience Center, 6001 Executive Blvd.,
Suite 3204, MSC 9529, Bethesda, MD 20892–
9529, 301–496–1917, webbere@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; Small Vessel Vascular
Contributions to Cognitive Impairment and
Dementia, (VCID) Biomarkers.
Date: July 13, 2016.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel and
Conference Center, 5701 Marinelli Road,
Bethesda, MD 20852.
Contact Person: Joel Saydoff, Ph.D.,
Scientific Review Administrator, Scientific
Review Branch, NINDS/NIH/DHHS,
Neuroscience Center, 6001 Executive Blvd.,
Suite 3204, MSC 9529, Bethesda, MD 20892–
9529, 301–496–9223, Joel.saydoff@nih.gov
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: June 21, 2016.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–15070 Filed 6–24–16; 8:45 am]
National Institutes of Health
BILLING CODE 4140–01–P
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel, F30 Conflict Review.
PO 00000
Frm 00082
Fmt 4703
Sfmt 4703
DEPARTMENT OF THE INTERIOR
National Park Service
[NPS–WASO–NRNHL–21277:
PPWOCRADI0, PCU00RP14.R50000]
National Register of Historic Places;
Notification of Pending Nominations
and Related Actions
National Park Service, Interior.
Notice.
AGENCY:
ACTION:
The National Park Service is
soliciting comments on the significance
of properties nominated before June 4,
2016, for listing or related actions in the
National Register of Historic Places.
DATES: Comments should be submitted
by July 12, 2016.
ADDRESSES: Comments may be sent via
U.S. Postal Service to the National
SUMMARY:
E:\FR\FM\27JNN1.SGM
27JNN1
]]>Agencies
[Federal Register Volume 81, Number 123 (Monday, June 27, 2016)]
[Notices]
[Pages 41588-41589]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-15057]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is co-owned by an agency of the
U.S. Government and is available for licensing and/or co-development in
the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to
achieve expeditious commercialization of results of federally-funded
research and development. Foreign patent applications are filed on
selected inventions to extend market coverage for companies and may
also be available for licensing and/or co-development.
ADDRESSES: Invention Development and Marketing Unit, Technology
Transfer Center, National Cancer Institute, 9609 Medical Center Drive,
Mail Stop 9702, Rockville, MD 20850-9702.
FOR FURTHER INFORMATION CONTACT: Information on licensing and co-
development research collaborations, and copies of the U.S. patent
applications listed below may be obtained by contacting: Attn.
Invention Development and Marketing Unit, Technology Transfer Center,
National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702,
Rockville, MD 20850-9702, Tel. 240-276-5515 or email
ncitechtransfer@mail.nih.gov. A signed Confidential Disclosure
Agreement may be required to receive copies of the patent applications.
SUPPLEMENTARY INFORMATION: Technology description follows.
Title of invention: Anti- B-Cell Maturation Antigen Antibodies for
Developing Cancer Therapeutics
Keywords: BCMA, Antibody, Immunotoxin, Chimeric Antigen Receptor
(CAR), Antibody-drug Conjugate (ADC), Bispecific Antibody, Cancer,
Myeloma,
Description of Technology: Multiple Myeloma is a subtype of
leukemia that originates in bone marrow, where normal plasma cells are
produced. Although FDA-approved antibody-based therapy is available for
other B-cell malignancies, no effective antibody-based therapies are
available for MM due to the lack of specific target antigen on MM
cells. BCMA (B-Cell Maturation Antigen), is a membrane antigen
selectively expressed on mature B-lymphocytes and in all MM cells from
patients. Thus, BCMA shows promise as a target for immune-based
therapy.
This technology concerns the generation of several monoclonal
antibodies against BCMA. These antibodies can be utilized
therapeutically in several ways, including as recombinant immunotoxins,
chimeric antigen receptors (CARs), antibody-drug conjugates (ADCs),
bispecific antibodies, and as unconjugated antibodies. The antibodies
can also be use in diagnostic applications. It is important to note
that several conjugated immunotoxins using the antibodies of this
invention have
[[Page 41589]]
already exhibited high efficacy against MM cells in recent in vitro
studies.
Potential Commercial Applications:
Therapeutic Uses
[cir] Use as an unconjugated antibody
[cir] Use as a targeting moiety for immunoconjugates such as CARs,
ADCs, immunoconjugates, bispecific antibodies, etc.
Diagnostic agent for detecting and monitoring BCMA-expressing
malignancies
Value Proposition:
First to market potential--There are no current targeted
therapeutics for BCMA
High specificity and binding to BCMA results in less non-
specific cell killing, therefore fewer potential side-effects for the
patient
Chimeric Antigen Receptor-based therapies have been successful
against B-cell lineage cancer; an anti-BCMA CAR represents a highly
effective therapeutic candidate
Development Stage: In-vitro testing.
Inventor(s): Ira Pastan (NCI), Tapan Bera (NCI), Satoshi Nagata
(Sanford Research Center), and Tomoko Ise (Sanford Research Center).
Intellectual Property:
US Provisional Application 62/255,255 (HHS Reference No. E-010-
2016/0-US-01) filed November 13, 2015 entitled ``Anti-BCMA Polypeptides
and Conjugates'';
US Provisional Application 62/257,493 (HHS Reference No. E-010-
2016/1-US-01) filed November 19, 2015 entitled ``Anti-BCMA Polypeptides
and Proteins''
Contact Information: Requests for copies of the patent application
or inquiries about licensing, and co-development research
collaborations should be sent to John D. Hewes, Ph.D. email:
john.hewes@nih.gov or phone: 240-276-5515.
Dated: June 20, 2016.
John D. Hewes,
Technology Transfer Specialist, Technology Transfer Center, National
Cancer Institute.
[FR Doc. 2016-15057 Filed 6-24-16; 8:45 am]
BILLING CODE 4140-01-P
